STMN2 and renal cell carcinoma: Relative to existing immunotherapy related signatures, the pan-cancer STMN2.SIG achieved markedly higher AUC values in RCC patients, highlighting its superior predictive capacity for immunotherapy response in RCC patients (Supplementary Figure S7B).